智通财经APP讯,中国生物制药(01177)发布公告,集团全资附属公司礼新医药科技(上海)有限公司(礼新医药)自主研发的创新药LM-350“CDH17 ADC”已获得美国食品药品监督管理局(FDA)的新药临床试验(IND)批件。
LM-350是基于礼新医药新一代抗体偶联药物(ADC)平台LM-ADCTM开发的一款靶向CDH17的ADC,能够高度选择性地结合CDH17,具有很强的内化能力。LM-350采用IgG1野生型构型,同时具备抗体依赖细胞介导的细胞毒性作用(ADCC)活性。临床前研究显示,LM-350在多个异种移植模型中表现出显著的抗肿瘤活性,尤其在对MMAE耐药或伊立替康耐药的结直肠癌细胞中效果突出。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.